Balyasny Asset Management
CRSP icon

Balyasny Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Balyasny Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-180,000
Closed -$9.34M – 1455
2018
Q3 		$9.34M Sell
180,000
-235,500
-57% -$12.3M 0.04% 511
2018
Q2 		$24.4M Buy
+415,500
New +$23.7M 0.11% 262

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management's CRSP Position: Q1 2026 in Review

Balyasny Asset Management sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 21,202 shares — an estimated $1.11M sold.

Balyasny Asset Management first reported a position in CRSP in Q2 2019 and held it in 14 quarters. The position peaked at $35.2M in Q4 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Balyasny Asset Management reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 21,202 CRISPR Therapeutics shares in Q1 2026, an estimated $1.11M.
  • Balyasny Asset Management first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 14 quarters.
  • Balyasny Asset Management's CRISPR Therapeutics position peaked at $35.2M in Q4 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.